Skip to main content
. 2023 May 4;40(6):2886–2901. doi: 10.1007/s12325-023-02518-w

Fig. 2.

Fig. 2

RAASi modifications after SZC initiation. Note: For the ZS-005 trial, patients were counted more than once if they required more than one RAASi adjustment so the total may exceed 100%. Rounding may cause differences of 1% or less among OPTIMIZE patient percentages. CKD chronic kidney disease; ESKD end-stage kidney disease; RAASi renin-angiotensin-aldosterone system inhibitors; SZC sodium zirconium cyclosilicate